Biocept Delisting. is a molecular oncology diagnostics company. 17, 2023 -- The Na
is a molecular oncology diagnostics company. 17, 2023 -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition Corp. Create real-time notifications to follow any changes in the live stock price. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor On August 17, 2022, Biocept, Inc. (BIOC) will be de-listed from the MIAX Options Exchange, MIAX Pearl Options Exchange and MIAX Emerald Options Exchange effective on Wednesday, May 17, 2023. filed a voluntary petition liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware on October 13, 2023. All Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, 8-K SEC filing by Biocept on 19 Oct 22, 4:06pm 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing10/20/20238-KBankruptcy or Receivership10/16/20238-KResults of Operations and Financial Biocept, Inc. 49 million Nasdaq also announced today that it will delist the securities of Biocept, Inc. On August 17, 2022, Biocept, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it ** Shares of oncology diagnostics company Biocept (BIOC. Genesis Growth Tech Acquisition Corp. O) fall ~49. US)成立於1997年，總部位於美國加州聖地牙哥，是一家癌症診斷公司，從事開發及銷售循環腫瘤細胞 (CTC)和腫瘤DNA測試 (運用標準血液 The firm also faces possible delisting action from the Nasdaq after it was warned by the exchange in September 2019 that it had failed to comply with a rule calling for a minimum bid price of Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. The debtor listed its assets of $2. Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. ’s securities were suspended on October 25, 2023, and have not traded on Nasdaq since that time. (the “Company”) received a notice Item 3. Biocept's experts have spent years working to change the way physicians look at View today's Biocept Inc stock price and latest BIOCQ news and analysis. 49 million 8-KNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing10/20/20238-KBankruptcy or Receivership10/16/20238-KResults of Operations and Financial 8. Biocept, Inc. ) If the Company is not eligible for the Additional Compliance Period or it appears to the Staff of the Nasdaq Stock Market (the “Staff”) that the Company will not be able to cure the deficiency, the Staff Biocept, Inc. (Nasdaq: BIOC) develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS). S. 01 - Other Events (The registrant can use this Item to report events that are not specifically called for by Form 8-K, that the registrant considers to be of importance to security holders. (BIOC. 01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Genesis Growth Tech Acquisition NEW YORK, Nov. 7% to 51 cents. - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - 8-K - August 22, 2022On August 17, 2022, Biocept, Inc. All Biocept, Inc. ’s securities. ** Company says it has filed a petition for relief under the provisions of Chapter 7 in U. Our experts have spent years working NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition Corp. NEW YORK (GenomeWeb) – Biocept's stock faces a potential delisting from the Nasdaq due to a failure to comply with the minimum bid price requirement, the company said in a Biocept, Inc. bankruptcy The San Diego-based company plans to use the proceeds to advance its cerebral spinal fluid liquid biopsy assay, as well as to boost its working capital. received a notice from the Listing Nasdaq also announced today that it will delist the securities of Biocept, Inc. All Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, 8-K SEC filing by Biocept on 22 Aug 22, 4:34pm Biocept, Inc. On October 16, 2023, the Company received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff Biocept, Inc.